$ADAP IPO $17 PT will be easy to do should $GSK / $MRK report favourable first data at #ASCO2020 from its Adaptimmune licensed NY-ESO-1 Specific T-Cells (#GSK3377794) Alone or in Combination with #Pembrolizumab in Relapsed and Refractory Multiple Myeloma